A review of erlotinib an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 2, 2010, Pages 311-320

  Iyer, Renuka ^a   Bharthuar, Anubha ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer; EGFR; Erlotinib; Oncology

Indexed keywords

CIMETIDINE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DILTIAZEM; DRUG METABOLITE; ERLOTINIB; GEMCITABINE; ITRACONAZOLE; KETOCONAZOLE; OSI 420; PLACEBO; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ALOPECIA; ANOREXIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; CORNEA PERFORATION; CORNEA ULCER; COUGHING; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; EYE IRRITATION; FATIGUE; FEVER; FOOD DRUG INTERACTION; GRAPEFRUIT; GRAPEFRUIT JUICE; GROUPS BY AGE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPATORENAL SYNDROME; HIRSUTISM; HUMAN; HYPERTRICHOSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERSTITIAL LUNG DISEASE; KERATOCONJUNCTIVITIS; KIDNEY FAILURE; LIVER FAILURE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUTH ULCER; NAIL COLOR DEFECT; NAIL DISEASE; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; PARONYCHIA; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SMOKING; STOMATITIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; EXANTHEMA; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 76749151364     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903551283     Document Type: Review

References (34)

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-187
2. Medinger M, Drevs J. Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des 2005;11:1139-1149
3. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550
4. Hamilton M, Wolf JL, Zborowski D, et al. Tarceva (erlotinib)exposure/ effects (EE) analysis from a phase III study in advanced NSCLC: effect of smoking on the PKof erlotinib [abstract 6165]. Proc Am Assoc Cancer Res 2005;46:1451
5. Ling J, Johnson KA, Miao Z, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006;34:420-426
6. Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Cancer Res 2006;1297:2166-2171
7. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279
8. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007;25:3055-3060
9. Jakacki RI, Hamilton M, Gilbertson RJ, et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 2008;26:4921-4927 [Epub ahead of print]
10. Broniscer A, Baker SJ, Stewart CF, et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res 2009;15:701-707
11. Christiansen SR, Broniscer A, Panetta JC, et al. Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature. Pharmacotherapy 2009;29:858-866
12. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006;8(Suppl 1):S7-14
13. Tarceva- [package insert]. Genentech, Inc. and OSI Pharmaceuticals, Inc.; South San Francisco, CA and Melville, NY, USA
14. Camp ER, Summy J, Bauer TW, et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor [review]. Clin Cancer Res 2005;11:397-405
15. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73, [Epub ahead of print]
16. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132
18. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966
19. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-6421
20. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899
21. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552
22. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC [abstract 8001]. J Clin Oncol 2009;27(Suppl):15
23. Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract LBA8002]. J Clin Oncol 2009;27(Suppl):18s
24. Johnson B, Miller V, Amler L, et al. Biomarker evaluation in the randomized, double-blind, placebo controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) [abstract 8LBA]. Eur J Cancer 2009;7(Suppl):5
25. Tang PA, Gill S, Au HJ, et al. Phase II trial of erlotinib in advanced pancreatic cancer [abstract 4609]. J Clin Oncol 2009;27(Suppl):15
26. Iyer R, Khushalani N, Tan W, et al. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) [abstract 6603]. Eur J Cancer 2009;7(Suppl):391
27. Boeck S, Vehling-Kaiserb U, Waldschmidtc D, et al. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anticancer Drugs 2010;21(1):94-100
28. Dickler MN, Cobleigh MA, Miller KD, et al. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009;115:115-121
29. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006;24:3069-3074
30. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-6663
31. Gravis G, Bladou F, Salem N, et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 2008;19:1624-1628
32. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909
33. Zhu CQ, da Cunha Santos G, Ding K, et al.; for the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275
34. Lee J, Jang K, Ki S, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007;109(8):1561-1569